The validity of Acuros BV and TG-43 for high-dose-rate brachytherapy superficial mold treatments

Boman, Eeva; Satherley, Thomas; Schleich, Nanette; Paterson, Dean B.; Greig, Lynne; Louwe, R.

doi:10.1016/j.brachy.2017.08.010

Cited by 22 publications

(24 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The resultant dose distribution from the bare source is hemispherical in the distal direction and reduces in intensity in the proximal direction due to x-ray absorption within the source body. 6,26 The nominal dose rate in water is 780, 125, 40, and 18 Gy h −1 at 10, 20, 30, and 40 mm, respectively. 7 The x-ray spectrum in air has a broad bremsstrahlung distribution with an average energy of 28 keV and characteristic lines from the tungsten thin film and yttrium in the anode body.…”

Section: C1 Axxent Model S700mentioning

confidence: 99%

Surface brachytherapy: Joint report of the AAPM and the GEC‐ESTRO Task Group No. 253

et al. 2020

View full text Add to dashboard Cite

The surface brachytherapy Task Group report number 253 discusses the common treatment modalities and applicators typically used to treat lesions on the body surface. Details of commissioning and calibration of the applicators and systems are discussed and examples are given for a risk-based analysis approach to the quality assurance measures that are necessary to consider when establishing a surface brachytherapy program.

show abstract

Section: C1 Axxent Model S700mentioning

confidence: 99%

Surface brachytherapy: Joint report of the AAPM and the GEC‐ESTRO Task Group No. 253

et al. 2020

View full text Add to dashboard Cite

show abstract

“…We have previously demonstrated that the dose difference between TG‐43 and Acuros BV calculations increase with increasing loading area for HDR brachytherapy surface mould treatments, resulting in a lower actual delivered dose than that seen with the TG‐43 dose calculation model . The dose difference seen at the prescription depth for scalp treatments was up to 16%.…”

Section: Discussionmentioning

confidence: 98%

“…In addition, for the scalp, the presence of bone might have more influence than that for the lower leg cases. One lower leg case (L1) had a FF mould, which is constructed in a different manner to the custom moulds; thus, the difference seen between TG‐43 and Acuros BV calculations might be different than those seen in the study of Boman et al . Currently, the American Brachytherapy Society (ABS) working group recommends not to use bolus as a backscatter material for skin HDR brachytherapy treatments.…”

Section: Discussionmentioning

confidence: 99%

“…Both Acuros BV and ACE have been shown to agree within ±2% with Monte Carlo method calculations for single‐source models, and specifically near the skin for breast brachytherapy patient models . We have recently shown that the delivered dose can be up to 15% lower at the prescription depth than that seen in the TG‐43 model for surface mould HDR brachytherapy and the difference increased with the skin lesion size (treatment area) . This might not be a significant issue when MBDCAs are accepted in clinical use .…”

Section: Introductionmentioning

confidence: 86%

See 1 more Smart Citation

Dosimetric comparison of surface mould HDR brachytherapy with VMAT

Boman

Paterson

Pearson

et al. 2018

J of Medical Radiation Sci

Self Cite

View full text Add to dashboard Cite

IntroductionThe aim of this study was to investigate the dosimetric differences between surface mould high‐dose‐rate (HDR) brachytherapy and external beam volumetric‐modulated arc therapy (VMAT) for two treatment sites.MethodsPreviously treated HDR brachytherapy surface mould scalp (n = 4) and lower leg (n = 3) treatments were retrospectively analysed. The VMAT plans were optimised using an additional 3‐mm setup margin on the clinical target volume (CTV) of the previously treated HDR plans. The HDR plans were calculated and normalised using the TG‐43 formalism and recalculated with Acuros BV (AC).ResultsOn average, the mean brain and normal tissue doses were reduced by 44.8% and 27.4% for scalp and lower leg VMAT cases, respectively, when compared to AC calculated HDR plans. For VMAT plans, the average dose to a 1‐mm thick skin structure deep to the target volume was not any lower than that in AC HDR plans. On average, the CTV coverage was 13.8% and 9.6% lower for scalp cases with AC dose calculation than with TG‐43 and 8.3% and 5.3% lower for lower leg cases if 0‐ or 1‐cm backscatter material was applied above the catheters, respectively.Conclusions VMAT is a feasible treatment option in the case of extensive skin malignancies of the scalp and lower leg. Uncertainties related to delivered dose with HDR brachytherapy when using the TG‐43 dose calculation model or possible air gaps between the mould and skin favour the use of VMAT. The potential soft tissue deformation needs to be considered if VMAT is used.

show abstract

“…TG-43 pomija wpływ tkanki, niejednorodność Natalia Matuszak / Zeszyty Naukowe WCO, Letters in Oncology Science 2017;14 (4):116-124 aplikatora oraz określone wymiary pacjentów. Obliczenia dawki przy użyciu formalizmu TG-43 dokonuje się wokół pojedynczego, centralnie umieszczonego źródła w kulistym fantomie wodnym [7][8][9][10][11][12][13][14][15]. Według założeń TG-186, dawki są wrażliwe na przekrój wspólnego oddziaływania woksel po wokselu, czyli w każdym elemencie objętości tkanki [16].…”

Section: • Pomiar Dawki Poprzez Tpsunclassified

Weryfikacja systemu do planowania leczenia w brachyterapii metodą TLD

Matuszak

2017

LOS

View full text Add to dashboard Cite

StreszczenieZjawisko termoluminescencji jest jedną z fundamentalnych metod luminescencji. Po napromienieniu, luminofor uwalnia energię zgromadzoną w postaci światła, o intensywności proporcjonalnej do pochłoniętej dawki. Emisja światła jest możliwa po uprzedniej ekspozycji promieniowaniem jonizującym bądź UV, a następnie wygrzaniu. Krzywe termoluminescencyjne obrazują efekt liniowego wzrostu temperatury, którym jest rejestracja ilości emitowanych kwantów luminescencji. Miarą pochłoniętej dawki jest amplituda piku równa scałkowanej powierzchni pod krzywą TL.Część fizyczną badań, obejmującą pomiary termoluminescencyjne przeprowadzono w Zakładzie Fizyki Jądrowej i Jej Zastosowań Uniwersytetu Śląskiego w Katowicach. Wszystkie czynności eksperymentalne dotyczące brachyterapii i tym samym wymagające użycia pożądanej aparatury zrealizowano w Zakładzie Radioterapii Katowickiego Centrum Onkologii.Weryfikacja opierała się na korelacji wyników dawek z planów leczenia, opartych na odmiennych algorytmach formalizujących obliczenia rozkładu dawki, z dawkami uzyskanymi na drodze pomiaru termoluminescencyjnego.Analiza wykazała, że metoda dozymetrii termoluminescencyjnej może być wykorzystana do weryfikacji dawek generowanych przez system planujący leczenie. Zgodność wyników jest możliwa przy uwzględnieniu wszystkich parametrów fizycznych pomiaru oraz warunków biologicznych. AbstractThermoluminescence is one of the fundamental luminescence methods. After irradiation, phosphor cumulates energy and then emits it as light with intensity proportional to absorbed dose. Emission of light follows prior exposure by ionization radiation or ultraviolet radiation and heating. Thermoluminescence curves are the result of a linear increase of temperature and show the amount of emitted luminescence quants. The dose absorbed is expressed by the peak amplitude which is equal to the integrated area under the TL curve Adres do korespondencji mg inż. Natalia Matuszak Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

show abstract

The validity of Acuros BV and TG-43 for high-dose-rate brachytherapy superficial mold treatments

Cited by 22 publications

References 22 publications

Surface brachytherapy: Joint report of the AAPM and the GEC‐ESTRO Task Group No. 253

Surface brachytherapy: Joint report of the AAPM and the GEC‐ESTRO Task Group No. 253

Dosimetric comparison of surface mould HDR brachytherapy with VMAT

Weryfikacja systemu do planowania leczenia w brachyterapii metodą TLD

Contact Info

Product

Resources

About